Genentech’s Actemra gets FDA breakthrough therapy status for scleroderma

Roche Group subsidiary Genentech has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for its Actemra (tocilizumab) to treat patients with systemic sclerosis (scleroderma).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news